Does hydrotherapy alleviate pain and improve functional mobility in patients with mucopolysaccharidosis type II (Hunter syndrome)?

Salford Royal Organisation, Northern Care Alliance NHS Foundation Trust0 sites5 target enrollmentOctober 25, 2023

Overview

Phase: 未知
Intervention: Not specified
Conditions: Mucopolysaccharidosis type II
Sponsor: Salford Royal Organisation, Northern Care Alliance NHS Foundation Trust
Enrollment: 5
Status: Active, not recruiting
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

October 25, 2023

End Date

October 30, 2024

Last Updated

2 years ago

Study Type

Interventional

Sex

Male

Sponsor

Salford Royal Organisation, Northern Care Alliance NHS Foundation Trust

•1\. Adult MPS II patients (Hunter syndrome; all males aged 18\-58 years), who suffer from joint pain and stiffness and/or post\-surgical musculoskeletal pain, not responding to analgesic agents
•2\. Patients with reduced mobility and wheelchair reliance
•3\. Patients are able to give consent and feedback. In patients with limited capacity, their carers/parents may be asked to help complete the questionnaires.
•4\. Participants who pass the Trust hydrotherapy risk assessment at baseline

•1\. Contraindications to standard hydrotherapy: acute diarrhoea or vomiting, recent acute cerebral vascular accident (CVA)/deep venous thrombosis (DVT)/pulmonary embolism (PE), resting angina, resting shortness of breath, uncontrolled cardiac failure, weight in excess of evacuation equipment, proven chlorine allergy.
•2\. More severely incapacitated (severe learning needs) and/or immobile patients.
•3\. The objective Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score will be used to identify and exclude patients who suffer from predominantly neuropathic pain (rather than musculoskeletal nociceptive\-driven pain). This assessment will be performed by a pain specialist.